NEW HAVEN, Conn., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that nearly 200 employees participated in the Company’s second annual “Arvinas Impact Day,” a company-wide community service day benefiting organizations in the Greater New Haven area.
"'Arvinas Impact Day' is a reflection of our company's unwavering dedication to community. It’s inspiring to see both local and remote colleagues transcend geographical boundaries to serve our community with passion and purpose,” said John Houston, Ph.D., chairperson, chief executive officer, and president at Arvinas. “Together, we’ve contributed to the expansion of important greater New Haven and youth science, technology, engineering, and math (STEM) initiatives while exemplifying Arvinas’ core value of community and our shared commitment to making a difference.”
Employees rolled up their sleeves and, through their collective efforts, helped make facility and grounds enhancements at a local non-profit organization, beautified the local environment with garbage pickup and clearing invasive species; prepared meals to be served to members of the New Haven Community; served as role models in a local school, helping to positively impact young people’s perceptions about the importance of education; and created STEM kits to be provided to foster youth across the country.
More specifically, Arvinas employees impacted the community through the following efforts:
“This day is a testament to the importance of giving back, aligning with our core values, and fostering a stronger, more inclusive community,” added Houston. “It is through our collective efforts that we can positively impact the lives of others and inspire change."
About Arvinas
Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC® Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC protein degraders against validated and “undruggable” targets, the company has three investigational clinical-stage programs: bavdegalutamide and ARV-766 for the treatment of men with metastatic castration-resistant prostate cancer; and vepdegestrant (ARV-471) for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. For more information, visit www.arvinas.com.
Arvinas Contacts
Media:
Kirsten Owens
203-584-0307
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investors:
Jeff Boyle
+1 (347) 247-5089
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$18.48 |
Daily Change: | 0.65 3.65 |
Daily Volume: | 1,657,624 |
Market Cap: | US$1.270B |
November 27, 2024 November 25, 2024 |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB